- Home
- DXYZ vs IRWD Comparison
DXYZ vs IRWD Comparison
Compare DXYZ & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | IRWD |
|---|---|---|
| Founded | N/A | 1998 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.0M | 520.6M |
| IPO Year | 2024 | 2010 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | IRWD |
|---|---|---|
| Price | $30.00 | $4.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.12 |
| AVG Volume (30 Days) | N/A | ★ 7.4M |
| Earning Date | N/A | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.01 |
| P/E Ratio | ★ N/A | $25.24 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $0.53 |
| 52 Week High | N/A | $5.78 |
Technical Indicators
Market Signals| Indicator | DXYZ | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 69.48 |
| Support Level | $26.84 | $3.87 |
| Resistance Level | $32.98 | $5.78 |
| Average True Range (ATR) | 1.64 | 0.36 |
| MACD | -0.42 | 0.07 |
| Stochastic Oscillator | 51.47 | 55.78 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.